AZYO Aziyo Biologics

Elutia to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

Elutia to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

SILVER SPRING, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a leader in drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, Matt Ferguson, Chief Financial Officer, and Dr. Michelle LeRoux Williams, Chief Scientific Officer, will participate in 1x1 investor meetings at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York on Thursday, November 21, 2024.

Institutional investors interested in meeting with management during the conference may reach out to their Canaccord representative.

About Elutia

Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visit .

Investors:

Matt Steinberg

FINN Partners



EN
13/11/2024

Underlying

AZYOAziyo Biologics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aziyo Biologics

 PRESS RELEASE
Free
AZYO AZIYO BIOLOGICS

Elutia Announces Strong Third Quarter Results, Accelerating Toward Ful...

Elutia Announces Strong Third Quarter Results, Accelerating Toward Full Launch of EluPro® Antibiotic-Eluting BioEnvelope in 2025 Over 100 EluPro VAC Submissions and 19% SimpliDerm Growth Drive Momentum into 2025 SILVER SPRING, Md., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, today provided a business update and financial results for the third quarter ended September 30, 2024. Business Highlights: First Commercial Use: Announced the first patient implant of EluPro, the FDA-cleared antibiotic-elut...

17h / 50m 1 EN
 PRESS RELEASE
Free
AZYO AZIYO BIOLOGICS

Elutia to Participate at the Canaccord Genuity MedTech, Diagnostics an...

Elutia to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum SILVER SPRING, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a leader in drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, Matt Ferguson, Chief Financial Officer, and Dr. Michelle LeRoux Williams, Chief Scientific Officer, will participate in 1x1 investor meetings at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York on Thursday, November 2...

November 13, 2024 1 EN
 PRESS RELEASE
Free
AZYO AZIYO BIOLOGICS

Elutia to Report Third Quarter 2024 Financial Results on Thursday, Nov...

Elutia to Report Third Quarter 2024 Financial Results on Thursday, November 14, 2024 SILVER SPRING, Md., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a leader in drug-eluting biomatrix products, today announced that it will release its third quarter 2024 financial results after market close on Thursday, November 14, 2024. Members of the Company’s management team will host a conference call and webcast starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day. The conference call can be accessed using the following information...

October 29, 2024 1 EN
 PRESS RELEASE
Free
AZYO AZIYO BIOLOGICS

Elutia to Present at the LD Micro Main Event XVII Conference on Wednes...

Elutia to Present at the LD Micro Main Event XVII Conference on Wednesday, October 30 SILVER SPRING, Md., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a leader in drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, will present at the LD Micro Main Event XVII Conference in Los Angeles on Wednesday, October 30, 2024, at 2:00 p.m. PT (5:00 p.m. ET). LD Micro Main Event XVII ConferencePresentation Date: Wednesday, October 30, 2024Presentation Time: 2:00 p.m. PT (5:00 p.m. ET)Webcast: Elutia management wi...

October 23, 2024 1 EN
 PRESS RELEASE
Free
AZYO AZIYO BIOLOGICS

Elutia Announces New Peer Reviewed Publication Highlighting the Robust...

Elutia Announces New Peer Reviewed Publication Highlighting the Robustness of EluPro™, Company’s Antibiotic-Eluting BioEnvelope for Implantable Devices EluPro eradicated bacteria commonly associated with cardiac implant-related infections in an established preclinical infection model SILVER SPRING, Md., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a leader in drug-eluting biomatrix products, today announced the publication of preclinical data demonstrating that EluPro, the world’s first antibiotic-eluting biologic envelope cleared by the U.S. Food and Drug Ad...

September 18, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch